DCVMN International, Route de Crassier 7, 1262 Nyon, Switzerland.
DCVMN International, Route de Crassier 7, 1262 Nyon, Switzerland.
Vaccine. 2021 Aug 16;39(35):4932-4937. doi: 10.1016/j.vaccine.2021.07.007. Epub 2021 Jul 13.
Vaccine manufacturers from developing countries have a proven track record of developing, producing, and supplying high-quality vaccines globally. However, due to the complexity of vaccine manufacturing, numerous stakeholder organizations support manufacturers across a variety of functions. To optimize the support from stakeholders it is instrumental to first understand which manufacturing processes these manufacturers require support for and what support functions are most beneficial. To this end, the Developing Countries Vaccine Manufacturers Network designed a comprehensive survey to assess the specific needs of the Network's member organizations. We found that almost all sampled manufacturers are interested in obtaining funding or technology transfers for COVID-19 vaccines. Furthermore, results indicated that manufacturers have a strong appetite for modern technology platforms, particularly RNA technologies. Scale-up, phase III clinical trials, and formulation were also key processes for which manufacturers require support.
发展中国家的疫苗制造商在全球范围内开发、生产和供应高质量疫苗方面有着良好的记录。然而，由于疫苗生产的复杂性，许多利益相关者组织在各种职能上支持制造商。为了优化利益相关者的支持，首先了解制造商需要哪些制造工艺的支持以及哪些支持功能最有帮助是至关重要的。为此，发展中国家疫苗制造商网络设计了一项全面的调查，以评估网络成员组织的具体需求。我们发现，几乎所有抽样制造商都有兴趣获得新冠疫苗的资金或技术转让。此外，结果表明，制造商对现代技术平台，特别是 RNA 技术有着强烈的兴趣。扩大规模、第三阶段临床试验和配方也是制造商需要支持的关键工艺。
